胰岛素的遗产:一个世纪的突破和创新
Somar Hadid1, Emily Zhang1, William H Frishman1,2
1From the School of Medicine, New York Medical College, Valhalla NY.
Cardiology in review
|March 13, 2024
概括
糖尿病的胰岛素疗法已经发展了100多年,从动物提取物到先进的输送系统和新的模拟胰岛素. 对于未来的创新,如对葡萄糖敏感胰岛素的研究仍在继续.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 医疗技术 医疗技术 医学技术
背景情况:
- 糖尿病的临床胰岛素使用始于一个多世纪前.
- 胰岛素治疗已经从动物提取物到生物工程人类胰岛素取得了显著的进步.
- 输送系统已经发展到自动化胰岛素输送系统.
研究的目的:
- 为了回顾胰岛素治疗的历史演变.
- 讨论各种胰岛素的药理学和适用情况,重点关注类似物.
- 突出胰岛素输送方面的进展,并应对可访问性挑战.
主要方法:
- 关于胰岛素治疗进展的文献综述.
- 讨论当前的胰岛素配方和输送系统.
- 分析胰岛素负担能力危机和未来研究方向.
主要成果:
- 胰岛素产品 (超快速,长效类型) 和输送系统 (胰岛素,自动输送) 的重大创新.
- 有证据支持自动化胰岛素输送系统的治疗益处.
- 负担能力危机影响了胰岛素的可获得性,目前正在努力改善它.
结论:
- 胰岛素治疗在过去一个世纪取得了显著的进步.
- 未来的创新,如对葡萄糖敏感的胰岛素和肝偏好性胰岛素是有前途的.
- 解决胰岛素负担能力问题对于公平的患者护理至关重要.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374
Insulin: Dosing Regimen and Adverse Effects
170
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
170
Insulin Formulations: Types and Delivery
193
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
193
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321


